A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42

BACKGROUND: The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based thera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet Oncol
Hauptverfasser: Mamounas, Eleftherios P., Bandos, Hanna, Lembersky, Barry C., Jeong, Jong-Hyeon, Geyer, Charles E., Rastogi, Priya, Fehrenbacher, Louis, Graham, Mark L., Chia, Stephen K., Brufsky, Adam M., Walshe, Janice M., Soori, Gamini S., Dakhil, Shaker R., Seay, Thomas E., Wade, James L., McCarron, Edward C., Paik, Soonmyung, Swain, Sandra M., Lawrence Wickerham, D., Wolmark, Norman
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6691732/
https://ncbi.nlm.nih.gov/pubmed/30509771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30621-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge